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Background: Sensorineural hearing loss is a well-known side effect of cisplatin (CDDP).
There is limited research on the effect of dosing, infusion times, and schedules of cisplatin
administration and their impact on hearing loss.
Methods: A retrospective review of 993 pediatric patients’ medical and audiological
charts from August 1990 to March 2015 was conducted using stringent inclusion criteria
to characterize patients with hearing loss. 248 of these patients received CDDP. Of these,
216 patients had sufficient CDDP infusion data to assess for sensorineural hearing loss
attributable to CDDP and its associated risk factors. Chart reviews were performed to
extract clinical data including CDDP dosing information. Demographic and clinical
characteristics were summarized by descriptive statistics, and univariate and
multivariate logistic regressions were performed to examine the relationship between
hearing loss and specific parameters of cisplatin administration (amount infused per dose,
prescribed infusion time, total number of doses, number of doses per cycle, number of
cycles, cumulative cisplatin exposure). Stepwise variable selection procedure was
performed in the multivariate model building to extract the best subset of risk factors
for the prediction of hearing loss and worsening ototoxicity grade using an established
ototoxicity grading scale from the International Society of Pediatric Oncology (SIOP).
Results: A total of 153 patients with complete medical and audiologic data were
evaluable for analysis. Hearing loss was identified in 72.6% of the patients. Multivariate
analysis revealed that age [OR=0.90 (0.84-0.97), p-value=0.0086], radiation to any part of
the body, [OR=3.20 (1.29-7.93), p-value=0.012], amount infused per dose (mg/m2)
[OR=1.018 (1.002-1.033), p-value=0.029], and cumulative cisplatin exposure (mg/m 2)
[OR=1.004 (1-1.008), p-value=0.027] were associated with hearing loss. Similar
associations were also found between these risk factors and worsening SIOP grade.
Conclusion: In one of the largest studies examining the influence of CDDP dosing and
schedules on hearing loss, we found the amount of CDDP infused per dose is a significant
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risk factor. Considerations in designing regimens that reduce the amount of CDDP infused
per dose may reduce the risk of hearing loss. Randomized prospective trials are needed.
Keywords: cisplatin, pediatric, cancer, ototoxicity, dosing
INTRODUCTION
Sensorineural hearing loss (SNHL) is a well-known complication
from the administration of cisplatin (CDDP) (1–6). Evidence
suggests there is long-term retention of CDDP in the cochlea,
and a dose-dependent relationship between a higher cumulative
dose and a higher incidence of hearing loss has been established
(7–9). Hearing loss may evolve during therapy, after its
completion, or may not even present until years following the
end of treatment (5, 10–12). Though the relationship between
hearing loss and CDDP has been thoroughly examined, the effect
of variables related to CDDP dosing and administration (the
amount per dose, frequency, and dosing schedules) and their
relationship to hearing loss have not been well-defined. This lack
of knowledge limits our ability to establish strategies for reducing
ototoxicity through modification of dosing parameters (4, 13,
14). Due to the limited research on this topic to date, we sought
to examine the relationship between parameters of CDDP dosage
or administration and the presence of hearing loss in a cohort of
pediatric cancer survivors.
PATIENTS AND METHODS
This study, approved by the Institutional Review Board of the
Washington University School of Medicine Human Research
Protection Office, was a retrospective chart review of medical
record data existing at the initiation of our study. Audiology
charts of pediatric oncology patients at St. Louis Children’s
Hospital treated from August 1, 1990 through March 31, 2015
were reviewed. From this cohort, patients were assessed for
treatment containing CDDP.
Inclusion criteria into our current study required prior CDDP
treatment. Patients whose chemotherapy treatment did not
include CDDP were excluded. Evaluable patients had either
completed their CDDP therapy or had documented CDDP
hearing loss from current therapy and were still being treated
at the cutoff for study entry in March 2015. Data was not
collected for patients still undergoing treatment who had
normal hearing at the cutoff point of the study. No patients
received oto-protectants. The medical records of these patients
were reviewed to extract the following variables of interest:
gender, birthdate, date of diagnosis, race, ethnicity, diagnosis,
CDDP dosage information (i.e. cumulative dose, number of
doses, amount per dose, doses per cycle, dosage time, dosage
reduction), presence of carboplatin, radiation exposure to any
part of body, radiation exposure to head, date when all therapy
ended, date of last CDDP administration, living status, date of
most recent audiogram, presence of hearing loss based on the
worse ear, and right/left ear toxicity grades according to the
International Society of Pediatric Oncology (SIOP) (15). Each
patient’s chart was individually evaluated for the specific
variables mentioned above; the actual dosing of CDDP
recorded in the medical record was used, and there was no
imputed data regarding the amount of CDDP the patient
received to ensure that the dosage information is patient
specific. We were unable to obtain consistent and specific
documentation of the infusion times for CDDP. Infusion times
utilized were the prescribed infusion times derived from the
patient’s orders or treatment plan. After review, thirty-two
patients were excluded as specific CDDP dosage information
was not available, resulting in a cohort of 216 patients eligible for
analysis in the current study.
A substantial effort was made to ensure clear audiologic data.
To uphold the audiologic parameters utilized in our previously
reported investigations, we adhered to formerly established
criterion to ensure the study subjects had treatment acquired,
ear specific, sensorineural hearing loss (16). This resulted in the
exclusion of many patients but created a pediatric population
with less ambiguous hearing profiles and allowed for a more
rigorous investigation into the presence of ototoxic hearing loss
in this population. The following details the stringent audiologic
parameters required for inclusion in this study.
Baseline Audiograms
All audiograms included in our analysis were of good to fair
reliability, as determined by the testing audiologist. Soundfield
and ABR testing was allowed for baseline testing. All patients
were required to have a normal baseline audiogram with a
subsequent ear specific behavioral audiogram, testing out to 6000
and/or 8000 Hz; baseline audiograms obtained via soundfield
testing were included as long as the subsequent hearing test
revealed ear specific thresholds. According to our institutional
standards, a normal behavioral hearing test was defined as
thresholds of ≤ 20 dB HL from 1 kHz - 4 kHz and ≤ 30 dB HL
at 6 kHz and 8 kHz, in order to account for tympanostomy tubes
and collapsing canals from earphones. A normal auditory brainstem
response (ABR) at our institution is defined as thresholds of ≤ 30
dBnHL from 0.5 kHz -1 kHz and ≤ 20 dBnHL at 2 kHz - 8 kHz,
using both earphone and inserts as transducers.
All evaluable baseline hearing tests required at least 2
thresholds from 1 kHz - 4 kHz. If any frequency was outside
the defined normal range, from 1kHz - 4kHz, the audiogram for
that ear was not evaluable. Ears with conductive hearing loss ≥
1000 Hz at baseline were excluded. Patients were included in our
analysis if they presented with normal hearing in at least one ear
at baseline. In this case, audiologic data was only collected on the
single, normal hearing ear. Finally, our study allowed the baseline
audiogram to be absent if a subsequent audiogram documented
normal hearing.
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Most Recent Audiograms
All audiograms evaluated as the “most recent audiogram” were
behavioral hearing tests; soundfield alone and ABR testing were
not permissible. All sensorineural hearing loss ≤ 4 kHz,
were confirmed by bone conduction thresholds. Bone is not
tested above 4 kHz at our institution. If the hearing loss was
observed at ≥ 6 kHz, documentation of a normal middle ear
status through static admittance of ≥ 0.3 mmho, large ear canal
volume consistent with patent tubes, and/or a normal otologic
exam by an otolaryngologist was needed to confirm
sensorineural nature of the hearing loss. In the current study,
the presence of normal bone conduction thresholds and/or a
normal hearing evaluation at both baseline and at the most
recent hearing test superseded abnormal tympanometric
measures. The patient was determined to have hearing loss if
the most recent audiogram showed change from normal baseline
and a SIOP grade of greater than 0 in the worse evaluable ear.
Each evaluable ear was assigned a SIOP grade relative to the
bone conduction thresholds of the most recent audiogram. The
SIOP grading scale has been suggested as the superior grading
scale in regards to classifying ototoxic hearing loss (17, 18).
Audiograms with a normal 4 kHz threshold but an absent or an
unevaluable 6 kHz and 8 kHz threshold were codified as “not
gradable test”, meaning that it could not utilize the SIOP
classification. For this study, SIOP grades 1 and 3 were based
on at least one obtained frequency referenced in the SIOP grade
level (6 or 8 kHz in grade 1 and 2 or 3 kHz in grade 3). Only 4
patients with hearing loss were not assigned a SIOP grade, as they
were still undergoing treatment. Assignment of a SIOP grade to a
patient with ongoing treatment would not accurately represent
the total ototoxic damage that may develop once the patient’s
CDDP treatment is completed.
Statistical Methods
Study data were collected and managed using REDCap electronic
data capture tools hosted at Washington University School of
Medicine (19, 20). REDCap (Research Electronic Data Capture)
is a secure, web-based software platform designed to support
data capture for research studies, providing 1) an intuitive
interface for validated data capture; 2) audit trails for tracking
data manipulation and export procedures; 3) automated export
procedures for seamless data downloads to common statistical
packages; and 4) procedures for data integration and
interoperability with external sources
All statistical analyses were carried out using SAS version 9.4
(SAS Institute, Cary, NC). Demographic and clinical characteristics
were summarized by descriptive statistics, i.e., median and IQR
(interquartile range) for continuous variables; and count and
percentage for categorical variables. Group differences were
examined by Kruskal-Wallis test for continuous variables and
Fisher’s exact test (if cell count less than 5) or Chi-square test for
categorical variables. Univariate and multivariate logistic regression
were used to examine the relationship between hearing loss/SIOP
grade and various risk factors, including sex, race, diagnosis,
carboplatin use, radiation, radiation to the head, age, total number
of doses, the amount of CDDP infused per dose, number of doses/
cycle, number of cycles, prescribed dose time, and cumulative
CDDP dose. A stepwise variable selection procedure was
performed in the multivariate model building for the outcome
measure, hearing loss. A significance level of 0.3 was required to
allow a risk factor to enter or stay in a model during the variable
selection process. To make the results comparable, the final
multivariate risk model of hearing loss that obtained during the
stepwise selection was used as the multivariate risk model for the
outcome measure, SIOP grade.
RESULTS
There were 993 patients in the entire cohort. After assessing their
treatment, 248 patients were included in the study who had a
prior history of CDDP exposure (Figure 1). Thirty-two patients
were excluded as specific CDDP dosage information was not
available. This resulted in a total of 216 evaluable patients for the
current study. Of the total 216 patients, 153 had sufficient
audiometric data necessary to assess their hearing status.
Table 1 summarizes the patient and treatment characteristics
based on the presence or absence of ototoxic hearing loss. The
demographics of patients included in this study are representative of
the general pediatric cancer population treated at St. Louis
Children’s Hospital – predominately Caucasian with a slight male
predominance. The diagnoses of patients in this study reflect patient
populations that undergo treatment regimens containing CDDP.
There were 111 patients (72.55%) with hearing loss, and 42
(27.45%) with normal hearing. Eight-five (55.6%) of patients were
male, and 68 (44.4%) were female. The average age of our patient
population was 8.3 years old, ranging from 0.2 to 19.9 years of age.
The mean time in years from the last CDDP administration to the
last recorded audiogram was 3.73 years (standard deviation= ± 3.77
years). Thirty-one patients (20.3%) were treated with carboplatin in
addition to CDDP. There were 91 patients (59.5%) who received
radiation, with 65 patients (42.5%) receiving radiation to the head.
The mean CDDP cumulative dose of 391.2 mg/m 2, ranging from
90 to 1000 mg/m 2. The mean amount per dose was 74.1 mg/m 2,
ranging from 20 to 150 mg/m 2. Patients received an average of 6.9
doses (range=1-30) and 3.7 cycles (range=1-8) with an average of
2.1 dose per cycle (range= 1-9). The average prescribed dose time
was 4.4 hours, (range= 1-8).
FIGURE 1 | CONSORT diagram outlining selection of eligible patients.
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Hearing Loss
Analysis of evaluable patients revealed a difference in hearing
loss frequency linked to age (p=0.0003), diagnosis (p= 0.0013),
radiation to any part of the body (p=0.010), radiation to the head
(p=0.012), amount of CDDP per dose (p=0.019), and number of
doses per cycle (p=0.048) (Table 1). Univariate binary logistic
regression analyses demonstrated that hearing loss was
associated with age (p= 0.0002), diagnosis (p=.0021), radiation
to any part of the body (p=0.011), radiation to the head
(p=0.014) and amount of CDDP per dose (p=0.01) (Table 2).
Multivariate binary logistic regression revealed younger age
[OR=0.90 (0.84-0.97), p = 0.0086], radiation to any part of the
body [OR= 3.2 (1.3-7.9), p=0.012], larger amount of CDDP per
dose [OR=1.018 (1.002-1.033), p=0.029], and larger cumulative
CDDP dose [OR=1.004 (1-1.008), p=0.027)] significantly
increased the risk of hearing loss (Table 2).
SIOP Grade
Univariate and multivariate multinomial logistic regression
analyses were also completed to determine associated risk
factors with SIOP grade (Table 3). Forty-one (27.9%)
individuals had a SIOP grade of 0, consistent with normal
hearing. Fifty-five (37.4%) of patients had a SIOP grade of 1-2,
and 51 (34.7%) had a SIOP grade of 3-4. Worsening SIOP grade
was associated with age (p<0.0001), diagnosis (p=0.011),
radiation to any part of the body (p=0.022), radiation to the
head (p=0.042), and amount of CDDP per dose (0.0093) on
univariate analysis. Like hearing loss, worsening SIOP grade was
associated with age (p <0.0001), radiation to any part of the body
(p=0.023), and amount of CDDP per dose (p=0.037) on
multivariate analysis, with cumulative dosing trending toward
significance (0.057) (Table 3).
DISCUSSION
Increasing our understanding of the parameters of CDDP
infusion effects on hearing loss can lead to strategies that may
reduce the risk. This study has demonstrated the amount of
CDDP infused per dose was strongly associated with an
TABLE 1 | Patient and treatment characteristics by the presence of hearing loss.
Characteristicsb Presence of Hearing Lossa
Total Yes No pc
No. of Patient 153 (100%) 111 (72.55%) 42 (27.45%)
SIOP Grade
0 41 (27.9%) 0 (0%) 41 (100%)
1-2 55 (37.4%) 55 (51.9%) 0 (0%)
3-4 51 (34.7%) 51 (48.1%) 0 (0%)
Age (Years) 153, 7.8 (3-13.3) 111, 6.1 (2.6-11.2) 42, 13.1 (7.2-16.2) 0.0003
Sex 0.3949
Male 85 (55.6%) 64 (57.7%) 21 (50%)
Female 68 (44.4%) 47 (42.3%) 21 (50%)
Race 0.9819
White 126 (83.4%) 91 (83.5%) 35 (83.3%)
Non-White 25 (16.6%) 18 (16.5%) 7 (16.7%)
Diagnosis 0.0013
Medulloblastoma 42 (27.5%) 35 (31.5%) 7 (16.7%)
Non- Medulloblastoma brain tumor 21 (13.7%) 18 (16.2%) 3 (7.1%)
Neuroblastoma 24 (15.7%) 21 (18.9%) 3 (7.1%)
Osteosarcoma 32 (20.9%) 15 (13.5%) 17 (40.5%)
Other 34 (22.2%) 22 (19.8%) 12 (28.6%)
Carboplatin Use 0.4962
Yes 31 (20.3%) 24 (21.6%) 7 (16.7%)
No 122 (79.7%) 87 (78.4%) 35 (83.3%)
Radiation 0.0100
Yes 91 (59.5%) 73 (65.8%) 18 (42.9%)
No 62 (40.5%) 38 (34.2%) 24 (57.1%)
Radiation to the Head 0.0121
Yes 65 (42.5%) 54 (48.6%) 11 (26.2%)
No 88 (57.5%) 57 (51.4%) 31 (73.8%)
Total Number of Doses 147, 6 (4-8) 107, 6 (4-8) 40, 6 (4-8) 0.2614
Amount of CDDP Infused Per Dose (mg/m2) 147, 75 (50-90) 107, 75 (50-100) 40, 60 (55-75) 0.0193
Number of Doses/Cycle 146, 1 (1-3) 106, 1 (1-4) 40, 2 (1-2.5) 0.0482
Number of Cycles 146, 4 (2-5) 106, 4 (2-5) 40, 4 (2-4.5) 0.8423
Prescribed Dose Time (hours) 122, 6 (4-6) 86, 6 (1.5-6) 36, 4 (4-6) 0.2135
Cumulative CDDP Dose (mg/m2) 153, 400 (300-480) 111, 400 (300-480) 42, 383.5 (299.7-480) 0.3272
aHearing loss defined by > 0 SIOP grade.
bFor categorical variables, (n (%)) is reported, excluding missing values. For continuous variables, “n, median (Q1-Q3)” is reported, where Q1 is 25th percentile, and Q3 is 75th percentile.
cFisher’s exact test (if cell count less than 5) or Chi-square test for categorical variable; Kruskal-Wallis test for continuous variable.
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increased risk of hearing loss; it is also associated with more
severe hearing loss as reflected by a worsening SIOP grade. Other
parameters such as number of doses, number of doses per cycle,
number of cycles, and infusion times failed to reach significance
using multivariate analysis. Cumulative CDDP was also
associated with hearing loss, to a lesser degree. Prior studies
have repeatedly identified cumulative incidence as a risk factor
for hearing loss (4, 11, 21). The relatively modest impact of
cumulative dosing of CDDP and hearing loss in this study may
be due to the relative lack of variance in our cohort in their
cumulative dosing (25th-75th percentile = 300-480 mg/m 2).
Thus, cumulative dosing may have been obscured as a risk
factor due to the minimal difference in cumulative dosing
between those with hearing loss and those without (mean =
400 mg/m2 vs. 383.5 mg/m2).
Our analysis also revealed age was strongly associated with a
risk of hearing loss with the youngest patients at greatest risk.
Radiation to any part of the body was also shown to be a risk
factor, with radiation directly to the head failing to achieve
significance in multivariate analysis. Our previous investigations
had established radiation to locations other than the head still
place patients at risk for hearing loss (16). Radiation can lead to
circulating free radicals and inflammatory mediators that have
been reported to impact organs and tissues distant from the organ
targeted for radiation (ascopal effect) (22, 23). It is likely radiation
to the head is also a risk factor for hearing loss given the
significant correlation observed in univariate analysis. Perhaps a
larger patient population would clarify its significance.
This report supports a recent study published which also
identified the amount per dose as a risk factor for hearing loss
(24). Our study can be distinguished from that report due to the
following differences. In the aforementioned study, baseline
audiograms were not required for the analysis; therefore there is
no assurance whether any of the patients had a pre-existing bilateral
or unilateral hearing loss prior to the initiation of CDDP therapy.
We continued to utilize the rigorous criteria we have used in
previous studies to ensure hearing loss in our subjects was a
consequence of acquired sensorineural hearing loss, excluding
ambiguous tests results. All of the subjects in our report were
tested in the same audiology department, using standardized
procedures and workflows with calibrated equipment in sound
suites minimizing interinstitutional variance. To be evaluable,
audiograms had to be of good to fair reliability with well-defined
parameters to exclude patients with pre-existing hearing loss.
Because our most recent audiograms required ear specific
thresholds for inclusion, we were able to attribute hearing loss on
the worse ear capturing the true effects of CDDP dosing on our
patients. We routinely utilize the worse ear to designate hearing loss
in our patients given the significant affect unilateral hearing loss can
have on quality of life (25). Standard of care at our institution
includes testing inter-octave thresholds when appropriate which
allows for accurate SIOP grading.
TABLE 2 | Univariate and multivariate binary logistic regression sasessing risk factors for the presence of hearing loss.
Risk Factors Univariate Multivariatea
Odds Ratio (95% CI) p-value Odds Ratio (95% CI) p-value

















Yes 2.561 (1.239-5.294) 3.197 (1.289-7.933)
No -ref- -ref-
Radiation to the Head 0.0139
Yes 2.67 (1.221-5.836)
No -ref-
Total Number of Doses 0.954 (0.896-1.015) 0.1380
Amount of CDDP Infused Per Dose (mg/m2) 1.018 (1.004-1.032) 0.0103 1.018 (1.002-1.033) 0.0287
Number of Doses/Cycle 0.91 (0.727-1.14) 0.4144
Number of Cycles 1.031 (0.825-1.289) 0.7859
Prescribed Dose Time (hours) 1.08 (0.902-1.294) 0.4000
Cumulative CDDP Dose (mg/m2) 1.002 (0.999-1.004) 0.2153 1.004 (1-1.008) 0.0271
aMultivariate stepwise selection results, where a significance level of 0.3 was required to allow a risk factor to enter or stay in a model during the variable selection process.
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Our audiometric data is representative of a purely pediatric
population; our mean age is older at 8.3 years. Obtaining reliable
data in a young, ill child is fraught with difficulties, leading to
audiograms that often fail to meet our stringent criteria for study
eligibility. Many audiograms in our youngest subjects were not
included in this study driving up the average age of the cohort.
Finally, we included hearing loss at all levels of severity, while the
recent publication only examined patients with higher SIOP
grades. We had previously shown hearing loss continues to
decline long after therapy is completed. We also have
demonstrated that the patients with the longest follow-up had
the highest likelihood of diagnosed hearing loss. Our mean time
in years from the last CDDP administration to the last
audiogram was 3.73 years while the previous study reported a
mean of 1.5 years from the end of treatment. The increased
prevalence of hearing loss as patients are followed longer and the
use of the better verses worse ear may explain the difference in
hearing loss observed by those investigators (43.8%) compared to
our study (72.6%) (24).This late onset hearing loss particularly
affects patients with established hearing loss at the completion of
therapy. Thus, even mild and unilateral CDDP associated
hearing loss is significant and warrants further follow-up.
This study was limited by the large fraction of patients (39%)
excluded for analysis due to missing infusion or audiology data.
.Ineligible patients were younger, more frequently treated with
carboplatin, and were less likely to be treated with radiation. We
suspect that these findings could be attributed to the differences
in the number of neuroblastoma patients in the ineligible cohort
(15.7% Eligible yes, 30.5% Eligible no). Neuroblastoma patients
are typically younger, may receive carboplatin, and may receive
less radiation due to their young age. Given the difficulties in
obtaining audiograms in young patients, it is possible that young
neuroblastoma patients were disproportionately excluded due to
insufficient audiologic data
The study was a cross sectional analysis with no specific time
point that could be used for hearing testing that could encompass
the entire cohort. Audiograms were not obtained after each
CDDP infusion so we could not assess any variables associated
with a specific infusion encounter. However, despite these
limitations and given the paucity of studies examining this
subject, our audiologic monitoring program provided evidence
that calls for new approaches for CDDP administration.
In order to increase the number of evaluable patients, we
included patients that demonstrated SNHL, even if they had not
TABLE 3 | Univariate and multivariate multinomial logistic regression assessing risk factors for SIOP grade.
Risk Factor SIOPa
Univariate Multivariateb
Odds Ratio (95% CI) p Odds Ratio (95% CI) p
Grade 1-2 Grade 3-4 Grade 1-2 Grade 3-4
Age (Years) 0.951 (0.881-1.027) 0.765 (0.692-0.846) <.0001 0.973 (0.89-1.062) 0.78 (0.697-0.872) <.0001
Sex 0.6909
Female 0.7 (0.31-1.583) 0.797 (0.349-1.819)
Male -ref- -ref-
Race 0.7766
Non-White 1.13 (0.389-3.278) 0.773 (0.247-2.414)
White -ref- -ref-
Diagnosis 0.0108
Medulloblastoma 1.978 (0.601-6.514) 3.429 (1.004-11.712)
Non- Medulloblastoma brain tumor 2.462 (0.527-11.5) 4 (0.835-19.162)
Neuroblastoma 2.462 (0.527-11.5) 5.778 (1.258-26.526)
Osteosarcoma 0.635 (0.212-1.902) 0.167 (0.03-0.917)
Other -ref- -ref-
Carboplatin Use 0.5360
Yes 1.079 (0.373-3.127) 1.662 (0.594-4.649)
No -ref- -ref-
Radiation 0.0223 0.0233
Yes 2.069 (0.909-4.708) 3.377 (1.413-8.069) 3.065 (1.121-8.384) 4.893 (1.437-16.653)
No -ref- -ref- -ref- -ref-
Radiation to the Head 0.0420
Yes 2.273 (0.951-5.431) 3.068 (1.269-7.419)
No -ref- -ref-
Total Number of Doses 0.955 (0.888-1.027) 0.949 (0.88-1.024) 0.2994
Amount of CDDP Infused Per Dose (mg/m2) 1.015 (1-1.031) 1.025 (1.009-1.042) 0.0093 1.019 (1.001-1.037) 1.026 (1.006-1.046) 0.0369
Number of Doses/Cycle 0.853 (0.652-1.116) 0.97 (0.753-1.25) 0.4653
Number of Cycles 1.048 (0.815-1.348) 0.96 (0.742-1.241) 0.7674
Prescribed Dose Time (hours) 1.094 (0.894-1.339) 1.055 (0.854-1.304) 0.6837
Cumulative CDDP Dose (mg/m2) 1.002 (0.999-1.005) 1.002 (0.999-1.005) 0.4528 1.005 (1.001-1.009) 1.005 (1-1.009) 0.0565
afor multinomial logistic regression, logits modeled use “SIOP Grade 0” as the reference category.
bto make the results comparable, the final multivariate risk model of hearing loss that obtained during the stepwise selection was used as the multivariate risk model for the outcome
measure, SIOP grade.
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completed therapy. However, we did not include patients
undergoing therapy if they had not demonstrated hearing loss
at the end of the study period. Given that our patients were
carefully screened for SNHL, which we would expect to be
irreversible, we were not concerned that patients who had
established SNHL would subsequently convert to the “no
hearing loss” cohort with time. In contrast, there are patients
who may lose hearing with subsequent cycles; this was our
justification for not including those patients receiving therapy
in the no hearing loss group. Furthermore, the patients with
hearing loss on therapy were not included in the SIOP analysis,
as it is possible the SIOP grade could shift, even while on therapy.
We therefore were able to add additional patients to enhance our
sample size, without including those subjects that would
compromise the integrity of the cohort.
This study also collected patients over a period of almost thirty
years. Although there have been advances in this field, there are no
significant changes in audiology testing that would have influenced
the data. However our monitoring of patients became more robust
in recent years, where we now test at risk patients at regular and set
intervals. Thus, the results may have been influence by the
frequency of testing rather than differences in testing methods.
We addressed this issue by examining the year of diagnosis (based
on the date of diagnosis) as a continuous variable. The year of date
of diagnosis ranges from 1983 to 2015 (median: 2006). The median
diagnosis year of patients with hearing loss is 2005 ranging from
1983 to 2015; while the median diagnosis year of non-hearing loss
group is 2007 ranging from 1996 to 2013. There is no significant
relationship between hearing loss and the year of diagnosis to the
date of the last audiogram, [OR = 0.96 (0.90- 1.03), p- = 0.22)].
Subgroup analysis comparing 2010-2015 to 1990-1995 also shows
the year of diagnosis has no significant relationship with hearing
loss (p = 0.16).
Although we examined specific infusion parameters, we were
unable to assess how patients may vary in CDDP exposure based on
varying pharmacokinetics. Such variations could lead to variances in
area underneath the curve (AUC) that could account for different
levels of toxicity. Calvert established a formula to establish more
consistent dosing and AUC attainment for carboplatin (26).
Unfortunately, due to the unpredictable pharmacokinetics of
cisplatin, comparable formulas have yet to be developed (18, 27).
More research is needed in this field.
Despite these limitations and given the paucity of studies
examining this subject, our audiologic monitoring program
provided evidence that calls for new approaches for
CDDP administration.
This project is one of the largest audiologic studies examining
the influence of CDDP dosing and schedules on hearing loss. We
demonstrated the amount of CDDP infused per dose is a
significant risk factor. These findings support an observation in
a previously reported clinical trial by the Children’s Oncology
Group where the two cohorts only varied with the amount of
CDDP per dose with worse ototoxicity observed in the group
assigned the higher dose (13). Such dosing can lead to higher
peak serum levels that can lead to greater penetration into the
cochlea. Given the recent studies demonstrating the persistent
retention of CDDP in the cochlea, alternative dosing with lower
amounts per dose may reduce CDDP accumulation in the
cochlea and may potentially lead to less ototoxicity while
retaining its anti-neoplastic properties. Prospective clinical
trials are needed.
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